Pro- and anti-inflammatory cytokines may influence proliferation, migration, invasion, and other cellular events of prostate cancer (PCa) cells. The hyaluronan receptor CD44, which is regulated by Interleukin (IL)-4, is a prostate basal cell marker. CD44high /CD49bhigh expressing cells have been demonstrated to have tumor-initiating characteristics. Here, we aimed to analyze the effects of long-term IL-4 treatment on CD44/CD49b expression, migration, proliferation, and clonogenic potential of basal-like PCa cells. To this end PC3 cells were treated over 30 passages with 5 ng/mL IL-4 (PC3-IL4) resulting in an increased population of CD44high expressing cells. This was concurrent with a clonal outgrowth of cuboid-shaped cells, with increased size and light absorbance properties. Flow cytometry revealed that the PC3-IL4 CD44high expressing subpopulation corresponds to the CD49bhigh population. Isolation of the PC3-IL4 CD44high /CD49bhigh subpopulation via fluorescence-associated cell sorting showed increased migrative, proliferative, and clonogenic potential compared to the CD44low /CD49blow subpopulation. In conclusion, IL-4 increases a PC3 subpopulation with tumor-initiating characteristics. Thus, IL-4, similar to other cytokines may be a regulator of tumor-initiation and hence, may present a suitable therapy target in combination with current treatment options.

Center of Biomolecular and Cellular Engineering International Clinical Research Center St Annés University Hospital Brno Brno Czech Republic

Department of Urology and Pediatric Urology University Medical Center Mainz Mainz Germany

Division of Experimental Urology Department of Urology Medical University of Innsbruck Innsbruck Austria

Zobrazit více v PubMed

Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012; 60:59–74. PubMed

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010; 329:568–571. PubMed PMC

Frame FM, Maitland NJ. Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol. 2011; 720:105–118. PubMed

Frame FM, Pellacani D, Collins AT, et al. HDAC inhibitor confers radiosensitivity to prostate stem‐like cells. Br J Cancer. 2013; 109:3023–3033. PubMed PMC

Smith BA, Sokolov A, Uzunangelov V, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci USA. 2015; 112:E6544–E6552. PubMed PMC

Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4:33–45. PubMed

Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res. 2010; 3:1–7. PubMed PMC

Patrawala L, Calhoun T, Schneider‐Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006; 25:1696–1708. PubMed

Trejdosiewicz LK, Morton R, Yang Y, Banks RE, Selby PJ, Southgate J. Interleukins 4 and 13 upregulate expression of cd44 in human colonic epithelial cell lines. Cytokine. 1998; 10:756–765. PubMed

Gee K, Kozlowski M, Kryworuchko M, Diaz‐Mitoma F, Kumar A. Differential effect of IL‐4 and IL‐13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95‐8 and in Epstein‐Barr virus (EBV) transformed human B cells: loss of IL‐13 receptors on Burkitt's lymphoma B cells. Cell Immunol. 2001; 211:131–142. PubMed

Mishra JP, Mishra S, Kumar A. STAT6 is a novel regulator of CD44 expression in human B cells (97.4). J Immunol. 2007; 178:S189–S189.

Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL‐4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999; 17:701–738. PubMed

Conticello C, Pedini F, Zeuner A, et al. IL‐4 protects tumor cells from anti‐CD95 and chemotherapeutic agents via up‐regulation of antiapoptotic proteins. J Immunol. 2004; 172:5467–5477. PubMed

Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000; 164:722–725. PubMed

Goldstein R, Hanley C, Morris J, et al. Clinical investigation of the role of interleukin‐4 and interleukin‐13 in the evolution of prostate cancer. Cancers (Basel). 2011; 3:4281–4293. PubMed PMC

Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF‐(kappa)B in interleukin‐4‐induced androgen receptor activation in prostate cancer cells. Prostate. 2005; 64:160–167. PubMed

Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC. Interleukin‐4 activates androgen receptor through CBP/p300. Prostate. 2009; 69:126–132. PubMed PMC

Culig Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta. 2011; 1813:308–314. PubMed

Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin‐4 stimulates androgen‐independent growth in LNCaP human prostate cancer cells. Prostate. 2008; 68:85–91. PubMed

Roca H, Craig MJ, Ying C, et al. IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation. J Cell Biochem. 2012; 113:1569–1580. PubMed PMC

Nappo G, Handle F, Santer FR, et al. The immunosuppressive cytokine interleukin‐4 increases the clonogenic potential of prostate stem‐like cells by activation of STAT6 signalling. Oncogenesis. 2017; 6:e342. PubMed PMC

Erb HHH, Langlechner RV, Moser PL, et al. IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. Endocr Relat Cancer. 2013; 20:677–689. PubMed PMC

Santer FR, Höschele PPS, Oh SJ, et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther. 2011; 10:1644–1655. PubMed

Vaux DL. Research methods: know when your numbers are significant. Nature. 2012; 492:180–181. PubMed

Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long‐term interleukin 6 (IL‐6) treatment express IL‐6 and acquire an IL‐6 partially resistant phenotype. Clin Cancer Res. 2001; 7:2941–2948. PubMed

Rojas A, Liu G, Coleman I, et al. IL‐6 promotes prostate tumorigenesis and progression through autocrine cross‐activation of IGF‐IR. Oncogene. 2011; 30:2345–2355. PubMed PMC

Puhr M, Hoefer J, Schäfer G, et al. Epithelial‐to‐Mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR‐200c and miR‐205. Am J Pathol. 2012; 181:2188–2201. PubMed

Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)‐integrin expression. J Cell Sci. 2001; 114:3865–3872. PubMed

Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 2004; 165:1543–1556. PubMed PMC

Petkova N, Hennenlotter J, Sobiesiak M, et al. Surface CD24 distinguishes between low differentiated and transit‐amplifying cells in the basal layer of human prostate. Prostate. 2013; 73:1576–1590. PubMed

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65:10946–10951. PubMed

Strand DW, Goldstein AS. The many ways to make a luminal cell and a prostate cancer cell. Endocr Relat Cancer. 2015; 22:T187–T197. PubMed PMC

Oldridge EE, Pellacani D, Collins AT, Maitland NJ. Prostate cancer stem cells: are they androgen‐responsive? Mol Cell Endocrinol. 2012; 360:14–24. PubMed

Zhang D, Park D, Zhong Y, et al. Stem cell and neurogenic gene‐expression profiles link prostate basal cells to aggressive prostate cancer. Nat Commun. 2016; 7:10798. PubMed PMC

Signoretti S, Waltregny D, Dilks J, et al. P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000; 157:1769–1775. PubMed PMC

Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015; 43:D805–D811. PubMed PMC

Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res. 2004; 64:5702–5711. PubMed

Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res. 2011; 17:6125–6129. PubMed PMC

Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin‐4. Cell Stem Cell. 2007; 1:389–402. PubMed

Di Stefano AB, Iovino F, Lombardo Y, et al. Survivin is regulated by interleukin‐4 in colon cancer stem cells. J Cell Physiol. 2010; 225:555–561. PubMed

Gaggianesi M, Turdo A, Chinnici A, et al. IL4 primes the dynamics of Breast cancer progression via DUSP4 inhibition. Cancer Res. 2017; 77:3268–3279. PubMed

Traub B, Sun L, Ma Y, et al. Endogenously expressed IL‐4Rα promotes the malignant phenotype of human pancreatic cancer in vitro and In vivo. Int J Mol Sci. 2017; 18:716. PubMed PMC

Takeshi U, Sadar MD, Suzuki H, et al. Interleukin‐4 in patients with prostate cancer. Anticancer Res. 2005; 25:4595–4598. PubMed

Mahon KL, Lin H‐M, Castillo L, et al. Cytokine profiling of docetaxel‐resistant castration‐resistant prostate cancer. Br J Cancer. 2015; 112:1340–1348. PubMed PMC

Lundin J, Kimby E, Bergmann L, Karakas T, Mellstedt H, Osterborg A. Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. Br J Haematol. 2001; 112:155–160. PubMed

Chiba Y, Todoroki M, Nishida Y, Tanabe M, Misawa M. A novel STAT6 inhibitor AS1517499 ameliorates antigen‐induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol. 2009; 41:516–524. PubMed